Translating these results towards clinical utility, we demonstrate BMP and LPG to be accessible biomarkers for CLN5 Batten disease in both plasma and dried blood spots, enabling early diagnosis and patient screening. This evidence concerns the gene CLN5 and juvenile neuronal ceroid lipofuscinosis.